Added: Jeanene Butcher - Date: 07.08.2021 19:06 - Views: 38772 - Clicks: 1955
Study record managers: refer to the Data Element Definitions if submitting registration or information. The proposed study is deed to investigate the non-inferiority of treatment of PsyD using monotherapy with quetiapine XR versus combination treatment using quetiapine XR and an SSRI sertraline or citalopram or escitalopram during the acute phase of treatment.
The secondary aim of the study is to assess the safety and efficacy of the combination of quetiapine XR and SSRIs in patients with the diagnosis of PsyD. Metabolic factors including fasting glucose, fasting insulin, and fasting lipids total cholesterol, HDL, LDL, and triglycerides will be obtained at screen and at the 8-week endpoint of the study to assess the impact of treatment on the development of risk factors for metabolic syndrome.
Information from the National Library of Medicine Choosing to participate in a study is an important Citalopram and seroquel decision. Talk with your doctor and family members or friends about deciding to a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. A patient with Diabetes Mellitus DM fulfilling one of the following criteria:. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or information.
Search for terms x. Save this study. Warning You have reached the maximum of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. First Posted : March 28, Last Update Posted : April 20, Study Description. The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.
Detailed Description:. Drug Information available for: Citalopram Quetiapine Quetiapine fumarate. FDA Resources. Arms and Interventions. Other Name: Quetiapine generic name : Seroquel brand name. Outcome Measures. Ham D 17 scores range from52 being the most severe. Scores range fromwith bring the most severe.
Scores range from with 42 referring to the worst functioning. CPFQ measured at baseline and 8 weeks. Neuropsychological Assessment. Scores range fromwith referring to higher cognitive functioning. Thus, they have a mean of average and a standard deviation of RBANS measured at baseline and 8 weeks. Cholesterol levels were collected at Baseline and Week 8. Level of triglycerides at Baseline and Week 8. HDL levels at Baseline and Week 8. LDL levels at Baseline and Week 8.
Blood hemoglobin A1C at Baseline and Week 8. Normal range: 3. Eligibility Criteria. Exclusion Criteria: Pregnancy or lactation Any DSM-IV Axis I disorder not defined in the inclusion criteria Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others Known intolerance or lack of response to quetiapine fumarate, as judged by the investigator Use of any of the following cytochrome P 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir Use of any of the following cytochrome P inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St.
John's Wort, and glucocorticoids Administration of a depot antipsychotic injection within one dosing interval for the depot before randomization Substance or alcohol dependence within the past three months except dependence in full remission, and except for caffeine or nicotine dependenceas defined by DSM-IV criteria Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrolment Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment Unstable or inadequately treated medical illness e.
Admitted to hospital for treatment of DM or DM related illness in past 12 weeks. Not under physician care for DM. Physician responsible for patient's DM care has not indicated that patient's DM is controlled. For thiazolidinediones glitazones this period should not be less than 8 Weeks. Patients who are currently treated Citalopram and seroquel antidepressants other than the selective serotonin reuptake inhibitors, with mood stabilizing or antipsychotic drugs other than quetiapine.
Patients with known arrhythmias or arrhythmias noted on screening EKG. Outpatients with a CGI score of 7. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. More Information. Layout table for additonal information Responsible Party: John D. National Library of Medicine U. National Institutes of Citalopram and seroquel U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Phase 4. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :.
Actual Primary Completion Date :. Actual Study Completion Date :. Experimental: Quetiapine Patients ased to receive Quetiapine. Other Name: Celexa. John D. August 10, Key Record Dates.Citalopram and seroquel
email: [email protected] - phone:(277) 854-5126 x 2009
Drug interactions with citalopram oral and quetiapine oral